Oral anticancer drugs: Back to square one

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 4, 2013, Pages 441-442

  Weitschies, W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLONANSERIN; IMATINIB; OPIATE; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SORAFENIB;

BIOEQUIVALENCE; CLINICAL PHARMACOLOGY; CONSTIPATION; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINAL SECRETIONS; LOW CALORY DIET; LOW FAT DIET; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; FOOD-DRUG INTERACTIONS; HUMANS;

EID: 84884479109     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.112     Document Type: Review

References (7)

1. Szmulewitz, R.Z. & Ratain, M.J. Playing Russian roulette with tyrosine kinase inhibitors. Clin. Pharmacol. Ther. 93, 242-244 (2013).
2. Tougas, G. et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am. J. Gastroenterol. 95, 1456-1462 (2000). (Pubitemid 30396302)
3. Tanaka, C. et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin. Pharmacol. Ther. 87, 197-203 (2010).
4. Davis, S.S., Hardy, J.G. & Fara, J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 27, 886-892 (1986). (Pubitemid 16044258)
5. Saruwatari, J. et al. Effect of dose timing in relation to food intake on systemic exposure to blonanserin. Eur. J. Clin. Pharmacol. 66, 899-902 (2010).
6. Heath, E.I. et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin. Pharmacol. Ther. 88, 818-823 (2010).
7. Heath, E.I. et al. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest. New Drugs 30, 1566-1574 (2012).